Research

Four pressing concerns drive research on liver diseases at Mount Sinai: the increase in chronic liver disease, the rapid growth of fatty liver disease throughout the population, the growing incidence of liver cancer and the shortage of organs for liver transplants. Basic, translational and clinical research in the Division of Liver Disease is geared toward finding solutions.

The division is particularly renowned for its leadership in the study of hepatic fibrosis, hepatocellular carcinoma, hepatitis C virus infection, primary biliary cirrhosis, and liver immunology.

Below are the basic research laboratories in the Division of Liver Diseases:

Autophagy During Hepatic Stellate

Clinical Outcomes & HCV Core Gene

Drug-induced Liver Injury Network (DILIN) Regional site

Genomics of Primary Biliary Cirrhosis 

Hepatic Autophagy, Progenitor Cells and fibrosis (SCOTT)

Hepatitis Outreach Network (HONE)

High-throughput sequencing of intrahepatic cholangiocarcinoma

HIV/HCV Center of Excellence

Implementation of Precision Medicine approaches in intrahepatic cholangiocarcinoma 

Minimally Invasive Biomarkers 

Prognostic Indicators

Molecular Prognostic Indicators in Liver Cirrhosis and Cancer 

Optimizing Vitamin D Treatment in HIV/AIDS

Project INSPIRE: CMS funded HCV care coordination program in coordination with the NYC Department of Health

 

These are the clinical research activities in the Division of Liver Diseases in the Department of Medicine.